Table 2.

Patient demographics

	Cases	PFS	OS
Subjects	n=253
Age	61.8 ± 11.4	0.002	0.001
Type of cancer
Ovarian cancer	224 (88.5%)	0.45	0.42
Primary peritoneal cancer	24 (9.5%)
Fallopian cancer	5 (2.0%)
Lymph nodes metastasis	99 (39.1%)	0.54	0.57
Lympho-vascular invasion	92 (36.4%)	0.006	0.001
FIGO Stage		0.09	0.08
IIIA and IIIB	7 (2.8%)
IIIC	211 (83.4%)
IV	35 (13.8%)
Histologic type		0.4	0.46
Serous	206 (81.4%)
Endometrioid	9 (3.6%)
Mucinous	5 (2.0%)
Undifferentiated	5 (2.0%)
Clear cell	5 (2.0%)
Mixed	21 (8.3%)
Other	2 (0.8%)
Tumor size	8.5 cm (1.2–24.5)	0.11	0.33
High grade tumor	194 (76.7%)	0.72	0.12
Preoperative CA-125	677 IU/L (8–5620)	0.006	0.03
Optimal surgery	105 (41.5%)	<0.001	<0.001
Bowel resection	88 (34.8%)	0.023	0.017
Type of chemotherapy
Carboplatin + Paclitaxel	119 (52.4%)	0.002	<0.001
Carboplatin + Docetaxel	72 (31.7%)
Cisplatin + Paclitaxel	34 (15.0%)
Carboplatin + Cyclophosphamide	2 (0.9%)
Number of cycles†	6 (0–12)	<0.001	<0.001
Chemotherapy response*	184 (81.0%)	<0.001	<0.001
Site of recurrence	196 (77.4%)
Extrapelvis	116 (68.2%)
Pelvis	31 (18.2%)
Chest	14 (8.2%)
Other	9 (5.3%)

Univariate analysis was performed between each variable and survival outcomes (PFS or OS) (P-value is shown). Comparisons of variables were performed for: ovarian vs primary peritoneal vs fallopian cancer for type of cancer; Stage III vs IV for FIGO Stage; serous vs non-serous for histology; and carboplatin + paclitaxel vs carboplatin + docetaxel vs cisplatin + paclitaxel vs carboplatin + cyclophosphamide. Crude tumor size and preoperative CA-125 were compared to survival.

^*227 cases with available response.

^†17 cases, no chemotherapy.

Abbreviations: PFS, progression-free survival; and OS, overall survival.